Overview
Trulicity is Eli Lilly’s dulaglutide, a once-weekly GLP-1 receptor agonist. It was among the first weekly GLP-1s to reach wide use, and for years it was a mainstay of type 2 diabetes management.
The essential point for anyone considering it for weight is this: Trulicity is approved for type 2 diabetes, not for weight management, and its weight effect is modest. Reported data puts mean weight loss at roughly 2 to 5 kg in clinical trials — a genuine effect, but far below the 15% or more of body weight seen with semaglutide at weight-management doses, or the 20% or more seen with tirzepatide.
Pricing does not reflect that gap. Eli Lilly publishes a list price of $1,006.93 per month, with other sources citing approximately $987.19, and the company states 90% of patients pay less than $75 — a figure that depends almost entirely on insurance coverage for a diabetes indication. Without coverage, reported cash prices have run around $991 to $1,394 depending on presentation and pharmacy.
That combination — brand-name pricing, a diabetes indication, and a weight effect well below newer agents — is why the same manufacturer’s tirzepatide products have largely superseded it for patients whose primary goal is weight loss. Trulicity remains a legitimate diabetes medication. It is rarely the right answer to a weight-loss question.
What Makes Trulicity Different
A Long-Established Weekly GLP-1
Dulaglutide has years of real-world use in type 2 diabetes management behind it. For a patient already stable on it with good glycaemic control, that track record is worth something and is not a reason to switch on its own.
Approved for Diabetes, Not Weight Management
Trulicity’s indication is type 2 diabetes. Any use aimed primarily at weight loss is off-label, which affects insurance coverage and means the weight-management dosing evidence that supports Wegovy or Zepbound does not apply here.
The Weight Effect Is Genuinely Modest
Reported mean weight loss of 2 to 5 kg in trials is a fraction of what semaglutide or tirzepatide achieve at weight-management doses. If weight loss is your goal, this gap is the single most important fact about the medication.
Coverage Makes or Breaks the Price
Lilly states 90% of patients pay less than $75, against a list price of $1,006.93. That spread is almost entirely about insurance coverage for a diabetes indication — the same coverage that is frequently unavailable for weight-loss use.
✓ Pros
- •FDA-approved with full agency review — safety, efficacy and manufacturing assessed
- •Once-weekly injection — not a daily regimen
- •Long real-world track record — years of use in type 2 diabetes management
- •90% of patients pay under $75 per Lilly — when covered for the diabetes indication
- •Established glycaemic benefit — this is a well-evidenced diabetes medication
- •Some weight effect — 2 to 5 kg mean reduction reported in trials
- •Familiar to prescribers — widely used and well understood clinically
✗ Cons
- •Not approved for weight management — weight-loss use is off-label
- •Weight effect far below newer agents — 2 to 5 kg versus 15%+ for semaglutide
- •List price of $1,006.93 per month — brand-name pricing for a modest weight effect
- •Cash prices up to around $1,394 reported — depending on presentation and pharmacy
- •Coverage for weight indications is rare — the low copays depend on diabetes coverage
- •Largely superseded for weight loss — by tirzepatide from the same manufacturer
- •Boxed warning for thyroid C-cell tumors — as with all GLP-1s in this class
- •Rarely offered by weight-loss telehealth — limited access outside diabetes care
Our #1 Recommended Provider
Trulicity is a diabetes medication with a modest weight effect at brand-name prices. If weight loss is your goal, Coreage RX offers semaglutide and tirzepatide at a flat $99 per month.
Medications Offered
Brand-Name or Compounded?
Brand-name, FDA-approved — for type 2 diabetes. Trulicity is dulaglutide, approved for type 2 diabetes and not for chronic weight management. Any use aimed primarily at weight loss is off-label. It carries full FDA review of safety, efficacy and manufacturing quality, unlike compounded preparations.
Trulicity (dulaglutide)
List price $1,006.93/month per Eli LillyA once-weekly subcutaneous GLP-1 receptor agonist available in multiple dose strengths. Lilly states 90% of patients pay less than $75, which depends on insurance coverage for the diabetes indication. Reported cash prices have ranged from around $991 to $1,394 depending on presentation and pharmacy.
Comparison: Ozempic (semaglutide)
Also a weekly GLP-1 for type 2 diabetesThe more commonly prescribed weekly GLP-1 for diabetes today, with a substantially greater weight effect than dulaglutide. If your clinician is choosing between diabetes GLP-1s and weight is a consideration, this comparison is the relevant one.
Comparison: Mounjaro (tirzepatide)
Eli Lilly’s dual GLP-1/GIP agonist for type 2 diabetesFrom the same manufacturer, with markedly greater glycaemic and weight effects than dulaglutide. Tirzepatide products have largely superseded Trulicity where weight is a treatment goal alongside glucose control.
If you are on Trulicity and doing well on it for diabetes management, this review is not an argument to switch — that is a decision for your clinician. If you are considering Trulicity primarily for weight loss, the mean 2 to 5 kg trial figure against 15% or more for semaglutide is the number that should drive the conversation.
Pricing, Membership & Medication Fees
| Cost Item | What You Pay |
|---|---|
| List price | $1,006.93 per month per Eli Lilly; other sources cite approximately $987.19 |
| With insurance | Lilly states 90% of patients pay less than $75 |
| Cash price reported | Around $991 for some presentations; up to $1,394 reported for a four-pen supply |
| Approved indication | Type 2 diabetes — weight-loss use is off-label |
| Dosing frequency | Once weekly |
| Mean weight loss in trials | Roughly 2 to 5 kg |
| Insurance for weight indications | Rarely available; the low copays reflect diabetes coverage |
| HSA / FSA | Prescription costs are commonly HSA/FSA eligible; confirm with your plan administrator |
The pricing here is only defensible with diabetes coverage. Paying $1,000 a month cash for a medication with a mean 2 to 5 kg weight effect makes little sense when compounded semaglutide is available from $99 and produces substantially more weight loss. With coverage at under $75, it is a reasonable diabetes medication.
How Trulicity Works
Establish Why It Is Being Prescribed
Trulicity is a diabetes medication. If it is being proposed primarily for weight loss, that is off-label use of a drug with a modest weight effect — ask your clinician directly why this rather than an agent approved for weight management.
Check Coverage for Your Indication
Lilly states 90% of patients pay less than $75, which reflects diabetes coverage. Plans commonly decline off-label weight-management prescriptions. Check your formulary before assuming the low copay applies to you.
Set Realistic Weight Expectations
Reported mean weight loss is roughly 2 to 5 kg in trials. If you are expecting the results associated with Wegovy or Zepbound, this medication will not deliver them, and knowing that upfront prevents abandoning a treatment that is working as intended for glucose control.
Inject Once Weekly
Trulicity is a once-weekly subcutaneous injection. Rotate injection sites, and follow the storage instructions — like all GLP-1 pens it is temperature-sensitive and requires refrigeration before first use.
Discuss Whether a Newer Agent Fits Better
If weight is a treatment goal alongside glucose control, ask about semaglutide or tirzepatide. Tirzepatide from the same manufacturer produces markedly greater weight and glycaemic effects, and that comparison is the one worth having.
Do Not Stop Abruptly
As with any GLP-1, do not discontinue without discussing it with your clinician, particularly if you are using it for glycaemic control where stopping affects blood sugar management directly.
Program Details at a Glance
| Detail | Trulicity |
|---|---|
| Medication class | GLP-1 receptor agonist. Dulaglutide, administered by once-weekly subcutaneous injection. |
| Approval status | FDA-approved for type 2 diabetes. Not approved for chronic weight management; weight-loss use is off-label. |
| Eligibility | Adults with type 2 diabetes per the approved indication, as assessed by a clinician. Off-label weight prescribing is a clinical judgement. |
| Provider involvement | Prescription-only. Diabetes management typically involves ongoing monitoring and dose adjustment. |
| Lab requirements | Determined by your clinician. Diabetes management typically involves regular HbA1c and related monitoring. |
| Pharmacy fulfillment | Dispensed through standard retail and mail-order pharmacy channels as an FDA-approved product, not through compounding pharmacies. |
| Dosing frequency | Once weekly subcutaneous injection, available in multiple dose strengths. |
| Support services | Eli Lilly operates patient support and savings programmes; check current eligibility terms directly. |
| Membership fee | Not applicable — this is a medication. Any programme fee depends on the provider you obtain it through. |
| Medication fee | List price $1,006.93 per month. Lilly states 90% of patients pay less than $75 with coverage. |
| Cancellation policy | Not applicable to the medication itself. Do not stop a GLP-1 abruptly without discussing it with your clinician. |
| Refund policy | Not applicable. Dispensed prescription medication is generally not returnable. |
| Insurance | Commonly covered for the approved type 2 diabetes indication. Coverage for off-label weight-management use is rare. |
| HSA / FSA | Prescription costs are commonly HSA/FSA eligible. Confirm with your plan administrator and keep itemised receipts. |
| Weight effect | Mean weight loss reported at roughly 2 to 5 kg in clinical trials. |
Who Trulicity Is Best For
✓ Best For:
- • Patients with type 2 diabetes for whom this is the approved indication
- • Anyone already stable on dulaglutide with good glycaemic control
- • Patients whose insurance covers Trulicity but not the newer agents
- • People who want a long-established weekly GLP-1 with an extensive real-world record
- • Patients for whom modest weight reduction alongside glucose control is sufficient
✗ Not Best For:
- • Anyone whose primary goal is meaningful weight loss
- • Patients paying cash without insurance coverage
- • People who could access semaglutide or tirzepatide instead
- • Anyone expecting results comparable to Wegovy or Zepbound
- • Patients with a personal or family history of medullary thyroid carcinoma or MEN2
- • People seeking a weight-management indication rather than off-label use
Limitations to Know Before You Sign Up
- ⚠Trulicity is approved for type 2 diabetes, not weight management. Use aimed primarily at weight loss is off-label, which affects insurance coverage and means weight-management dosing evidence does not apply.
- ⚠The weight effect is modest. Reported mean weight loss of roughly 2 to 5 kg in trials is a fraction of what semaglutide achieves at weight-management doses, let alone tirzepatide.
- ⚠The list price of $1,006.93 per month is brand-name pricing. Lilly states 90% of patients pay less than $75, but that depends on insurance coverage for a diabetes indication that is frequently unavailable for weight use.
- ⚠Tirzepatide products from the same manufacturer have largely superseded dulaglutide where weight is a treatment goal alongside glucose control.
- ⚠Like all GLP-1 receptor agonists in this class, dulaglutide carries a boxed warning regarding thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
- ⚠Trulicity is rarely offered through weight-loss telehealth platforms, so access outside diabetes care is limited.
Alternatives to Trulicity
Wegovy / Ozempic
FDA-approved semaglutide with substantially greater weight loss, including a weight-management indication.
Mounjaro / Zepbound
Eli Lilly’s tirzepatide, with markedly greater weight and glycaemic effects than dulaglutide.
Rybelsus
Oral semaglutide for type 2 diabetes, if avoiding injection matters more than maximising weight effect.
Saxenda
Liraglutide approved for weight management, though being discontinued in early 2027.
Frequently Asked Questions
Is Trulicity approved for weight loss?
No. Trulicity is FDA-approved for type 2 diabetes. Any use aimed primarily at weight loss is off-label, which affects insurance coverage and means the weight-management dosing evidence supporting Wegovy or Zepbound does not apply to it.
How much weight can you lose on Trulicity?
Reported data puts mean weight loss at roughly 2 to 5 kg in clinical trials. That is a genuine effect but far below the 15% or more of body weight associated with semaglutide at weight-management doses, or the 20% or more associated with tirzepatide.
How much does Trulicity cost?
Eli Lilly publishes a list price of $1,006.93 per month, with other sources citing approximately $987.19. Lilly states 90% of patients pay less than $75, which depends on insurance coverage for the diabetes indication. Reported cash prices have ranged from around $991 to $1,394 depending on presentation and pharmacy.
Is Trulicity as good as Ozempic?
For weight, no. Semaglutide produces substantially greater weight loss than dulaglutide. For glycaemic control both are established diabetes medications, and the choice between them is a clinical decision. Where weight is a treatment goal alongside glucose control, the newer agents generally win the comparison.
Why is Trulicity less commonly prescribed now?
Newer agents have largely superseded it where weight matters. Tirzepatide from the same manufacturer produces markedly greater weight and glycaemic effects, and semaglutide products carry weight-management indications that dulaglutide does not.
Can I get Trulicity through a weight-loss telehealth provider?
Rarely. Trulicity is not commonly offered through weight-loss telehealth platforms, since it is a diabetes medication with a modest weight effect. Access is generally through diabetes care rather than weight-management services.
How often do I take Trulicity?
Once weekly by subcutaneous injection, available in multiple dose strengths. Like all GLP-1 pens it is temperature-sensitive and requires refrigeration before first use — follow the dispensing instructions on storage and disposal.
What are the main risks?
Like all GLP-1 receptor agonists in this class, dulaglutide carries a boxed warning regarding thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Gastrointestinal side effects are common. Pancreatitis is among the serious risks to discuss with your clinician.
The Bottom Line
Trulicity earns 2.5 out of 5 stars — not because it is a bad medication, but because it is the wrong medication for the question most people arriving at this page are asking.
As a type 2 diabetes treatment, dulaglutide is legitimate, well established and backed by years of real-world use. If you are on it, doing well, and your glycaemic control is good, nothing here is an argument to switch — that is a conversation for your clinician, not a review site.
As a weight-loss medication, it is difficult to justify. It is not approved for weight management, so that use is off-label. Its reported mean weight loss of 2 to 5 kg is a fraction of what semaglutide and tirzepatide deliver. And its list price of $1,006.93 per month is full brand-name pricing for that modest effect — defensible only with diabetes coverage bringing it under $75, which is precisely the coverage plans decline for weight indications.
Our recommendation: if weight loss is your goal, this is not the medication, and the same manufacturer makes a better one. Discuss tirzepatide or semaglutide with your clinician instead. If cost is the barrier, compounded routes such as Coreage RX at a flat $99 deliver far more weight loss for a tenth of Trulicity list pricing.
Disclosure:
This review is based on publicly available information including Eli Lilly’s published Trulicity pricing information, FDA labelling information, published clinical data on dulaglutide weight effects, and independent pharmacy pricing sources, current as of August 27, 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews; we have no relationship with Eli Lilly. Trulicity is approved for type 2 diabetes and is not approved for weight loss; any use for weight management is off-label and is a decision for you and your clinician. List prices are not what most patients pay — insurance coverage, savings programmes and pharmacy pricing all vary substantially. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This review is for informational purposes only and is not medical advice, diagnosis, or treatment. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. Never start, stop, or change a prescription based on this page. If you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, or other concerning symptoms, seek medical care immediately. See our full medical disclaimer.
Or check out our top-rated provider